JUNIPER PUBLISHERS-OPEN ACCESS JOURNAL OF CARDIOLOGY & CARDIOVASCULAR THERAPY Abstract One of the clinical situations linked to the use of warfarin is the skin necrosisoccurring in approximately 0.01 to 0.1% of all patients receiving warfarin. Typically, lesions develop during the first days after initiation of warfarin therapy (usually around the tenth day) and are often associated with the administration of a loading dose. The pathophysiological mechanisms for warfarin-induced skin necrosis, despite several theories, remain uncertain. For the diagnosis, along with a high degree of suspicion, a rapid recognition and management is required. Introduction Warfarin-induced skin necrosis (WISN) is a complication of therapy with coumarinassociated with a high morbidity and mortality [1]. In 1943, the necrotic changes were first time described on the skinof a patient taking warfarin, at that time it was called “disseminated thrombophlebitis migrans” [2] and were n
